Skip to main content

Table 3 Unadjusted survival proportions in overall microscopically confirmed stages I–II and III–IV pancreatic cancer patients

From: Stratified survival of resected and overall pancreatic cancer patients in Europe and the USA in the early twenty-first century: a large, international population-based study

Time

USA

The Netherlands

Belgium

Norway

Slovenia

Stages I–II

Stages III–IV

Stages I–II

Stages III–IV

Stages I–II

Stages III–IV

Stages I–II

Stages III–IV

Stages I–II

Stages III–IV

OS (95% CI)a

OS (95% CI)

OS (95% CI)

OS (95% CI)

OS (95% CI)

OS (95% CI)

OS (95% CI)

OS (95% CI)

OS (95% CI)

OS (95% CI)

1 month

  ≤ 60 years

96 (95–96)

77 (76–78)

98 (97–99)

87 (86–89)

98 (97–99)

93 (91–95)

99 (96–100)

92 (90–94)

98 (93–99)

87 (82–90)

 60–69 years

93 (92–93)

72 (71–72)

96 (95–97)

83 (82–84)

97 (96–98)

89 (87–91)

97 (94–98)

87 (85–89)

97 (92–99)

82 (77–86)

  ≥ 70 years

84 (84–85)

60 (59–61)

92 (90–93)

74 (72–75)

93 (92–94)

81 (80–83)

96 (94–98)

80 (78–82)

94 (90–97)

67 (63–72)

3 months

  ≤ 60 years

90 (90–91)

59 (58–60)

93 (91–94)

61 (59–63)

95 (93–96)

78 (75–80)

96 (93–98)

67 (63–70)

95 (90–98)

61 (55–67)

 60–69 years

86 (85–87)

53 (53–54)

89 (87–91)

55 (53–57)

92 (91–94)

69 (67–71)

91 (88–94)

59 (56–62)

93 (88–96)

54 (48–59)

  ≥ 70 years

71 (71–72)

40 (39–40)

79 (77–81)

42 (41–44)

83 (81–84)

55 (53–56)

85 (82–88)

44 (42–47)

81 (75–86)

39 (35–44)

6 months

  ≤ 60 years

81 (80–82)

41 (40–42)

83 (81–86)

36 (34–37)

90 (87–92)

59 (56–62)

88 (82–91)

43 (39–46)

92 (85–95)

44 (38–49)

 60–69 years

74 (73–75)

35 (35–36)

79 (77–81)

32 (31–34)

86 (83–88)

50 (48–53)

79 (74–83)

37 (34–40)

82 (74–87)

40 (34–45)

  ≥ 70 years

57 (56–57)

24 (24–25)

63 (61–66)

22 (21–23)

67 (65–69)

34 (32–35)

67 (63–71)

22 (20–24)

70 (63–76)

19 (16–23)

12 months

  ≤ 60 years

60 (58–61)

20 (20–21)

62 (59–65)

13 (12–15)

72 (69–76)

31 (28–34)

65 (58–71)

20 (17–23)

65 (56–72)

17 (13–22)

 60–69 years

54 (52–55)

17 (17–18)

57 (54–59)

12 (11–13)

65 (62–68)

24 (22–26)

55 (49–60)

13 (11–15)

59 (50–66)

19 (15–24)

  ≥ 70 years

36 (35–36)

10 (10–11)

40 (38–42)

7 (7–8)

43 (40–45)

14 (13–15)

42 (37–46)

7 (6–9)

49 (42–56)

7 (5–10)

24 months

  ≤ 60 years

36 (34–37)

7 (6–7)

31 (28–34)

4 (4–5)

47 (43–51)

10 (9–12)

39 (32–46)

7 (5–9)

35 (27–43)

6 (3–9)

 60–69 years

30 (29–31)

5 (5–6)

30 (27–33)

3 (2–3)

38 (35–41)

6 (4–7)

30 (25–35)

3 (2–4)

24 (18–31)

4 (2–6)

  ≥ 70 years

18 (17–19)

3 (3–3)

20 (18–22)

2 (1–2)

21 (19–22)

3 (3–4)

19 (16–23)

2 (1–3)

25 (19–31)

2 (1–4)

36 months

  ≤ 60 years

26 (24–27)

3 (3–4)

21 (18–24)

2 (2–3)

34 (30–37)

5 (4–7)

25 (19–32)

4 (2–6)

23 (16–30)

2 (1–4)

 60–69 years

20 (19–21)

2 (2–3)

19 (17–22)

1 (1–2)

25 (22–28)

2 (1–3)

19 (14–24)

1 (< 1–2)

14 (9–20)

2 (1–3)

  ≥ 70 years

12 (11–12)

1 (1–2)

14 (12–16)

1 (< 1–1)

13 (11–14)

1 (1–2)

13 (10–17)

1 (< 1–1)

14 (9–19)

1 (< 1–2)

60 months

  ≤ 60 years

19 (18–20)

2 (1–2)

14 (12–17)

1 (1–1)

23 (19–26)

2 (1–3)

16 (11–22)

1 (< 1–2)

15 (9–23)

2 (1–4)

 60–69 years

13 (12–14)

1 (1–1)

12 (10–14)

< 1 (< 1–1)

16 (14–19)

1 (< 1–1)

13 (9–18)

< 1 (< 1–1)

8 (4–14)

1 (< 1–3)

  ≥ 70 years

7 (7–8)

1 (< 1–1)

7 (6–9)

< 1 (< 1–1)

7 (6–8)

1 (< 1–1)

8 (5–11)

< 1 (< 1–1)

8 (5–13)

< 1 (< 1–1)

  1. OS overall survival, CI confidence interval
  2. aData are shown as survival proportion (95% confidence interval) [%]